Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$47.98 - $54.4 $3.9 Million - $4.42 Million
81,304 Added 245.97%
114,358 $6.2 Million
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $2.36 Million - $2.82 Million
-48,733 Reduced 59.59%
33,054 $1.7 Million
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $129,326 - $144,606
2,234 Added 2.81%
81,787 $4.75 Million
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $149,017 - $165,460
2,339 Added 3.03%
79,553 $5.09 Million
Q1 2023

Apr 28, 2023

SELL
$65.71 - $74.53 $149,818 - $169,928
-2,280 Reduced 2.87%
77,214 $5.35 Million
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $32,391 - $38,355
-473 Reduced 0.59%
79,494 $5.72 Million
Q2 2022

Aug 04, 2022

SELL
$72.62 - $79.98 $338,990 - $373,346
-4,668 Reduced 5.52%
79,967 $6.16 Million
Q1 2022

May 05, 2022

BUY
$61.48 - $73.72 $2.04 Million - $2.45 Million
33,233 Added 64.65%
84,635 $6.18 Million
Q4 2021

Jan 31, 2022

SELL
$53.63 - $62.52 $1.12 Million - $1.31 Million
-20,939 Reduced 28.94%
51,402 $3.21 Million
Q3 2021

Oct 29, 2021

BUY
$59.17 - $69.31 $236,029 - $276,477
3,989 Added 5.84%
72,341 $4.28 Million
Q2 2021

Jul 29, 2021

BUY
$61.91 - $67.42 $337,161 - $367,169
5,446 Added 8.66%
68,352 $4.57 Million
Q1 2021

Apr 26, 2021

BUY
$59.34 - $66.74 $3.73 Million - $4.2 Million
62,906 New
62,906 $3.97 Million
Q1 2020

Apr 27, 2020

SELL
$46.4 - $67.43 $2.17 Million - $3.15 Million
-46,745 Closed
0 $0
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $9,842 - $12,838
200 Added 0.43%
46,745 $3 Million
Q3 2019

Oct 17, 2019

BUY
$42.77 - $50.71 $1.99 Million - $2.36 Million
46,545 New
46,545 $2.41 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Beacon Harbor Wealth Advisors, Inc. Portfolio

Follow Beacon Harbor Wealth Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beacon Harbor Wealth Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Beacon Harbor Wealth Advisors, Inc. with notifications on news.